20 years of historical data (2005–2024) · Healthcare · Biotechnology
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
Valneva SE currently has a negative P/E ratio, indicating the company is operating at a loss on a trailing-twelve-month basis.
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $963M | $307M | $719M | $734M | $2.7B | — | — | — | — | — | — |
| Enterprise Value | $1.0B | $355M | $802M | $597M | $2.5B | — | — | — | — | — | — |
| P/E Ratio → | -55.31 | — | — | — | — | — | — | — | — | — | — |
| P/S Ratio | 4.82 | 1.81 | 4.68 | 2.03 | 7.78 | — | — | — | — | — | — |
| P/B Ratio | 3.64 | 1.69 | 5.60 | 3.34 | 15.88 | — | — | — | — | — | — |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | 35.23 | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
Valneva SE's enterprise value stands at 26.3x EBITDA, 144% above its 5-year average of 10.8x. The Healthcare sector median is 13.8x, placing the stock at a 90% premium on an enterprise-value basis.
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 2.09 | 5.21 | 1.65 | 7.12 | — | — | — | — | — | — |
| EV / EBITDA | 26.27 | 10.79 | — | — | — | — | — | — | — | — | — |
| EV / EBIT | 64.88 | 28.41 | — | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — | — | — | — |
Margins and return-on-capital ratios measuring operating efficiency
Valneva SE earns an operating margin of 7.9%. Operating margins have expanded from -31.4% to 7.9% over the past 3 years, signaling improving operational efficiency. A negative ROE of -7.9% indicates the company is currently destroying shareholder equity. ROIC of 4.5% represents below-average returns on invested capital.
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 41.9% | 41.9% | 34.4% | 10.2% | 46.0% | 50.8% | 60.4% | 61.6% | 56.3% | 54.2% | 40.1% |
| Operating Margin | 7.9% | 7.9% | -53.4% | -31.4% | -17.6% | -50.0% | -0.6% | 5.5% | -3.8% | -45.3% | -25.4% |
| Net Profit Margin | -7.2% | -7.2% | -66.0% | -39.7% | -21.1% | -58.4% | -1.4% | 2.9% | -10.9% | -52.3% | -26.3% |
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -7.9% | -7.9% | -58.3% | -73.4% | -59.2% | -60.6% | -1.3% | 2.8% | -11.9% | -40.3% | -15.3% |
| ROA | -2.6% | -2.6% | -18.8% | -19.9% | -11.6% | -18.0% | -0.7% | 1.6% | -5.8% | -20.4% | -8.2% |
| ROIC | 4.5% | 4.5% | -41.9% | -797.3% | — | -61.5% | -0.4% | 3.7% | -2.1% | -18.1% | -8.0% |
| ROCE | 3.9% | 3.9% | -25.4% | -28.6% | -17.0% | -22.2% | -0.4% | 3.7% | -2.5% | -21.5% | -9.3% |
Solvency and debt-coverage ratios — lower is generally safer
Valneva SE carries a Debt/EBITDA ratio of 6.6x, which is highly leveraged (111% above the sector average of 3.1x). Net debt stands at $48M ($216M total debt minus $168M cash). Interest coverage of just 0.6x is concerning — the company has limited headroom to absorb earnings volatility before struggling with debt service.
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 1.19 | 1.19 | 1.63 | 0.69 | 0.67 | 1.36 | 0.63 | 0.40 | 0.77 | 0.82 | 0.71 |
| Debt / EBITDA | 6.57 | 6.57 | — | — | — | — | 11.04 | 4.40 | 9.95 | — | — |
| Net Debt / Equity | — | 0.27 | 0.65 | -0.62 | -1.36 | -1.28 | 0.15 | -0.14 | 0.41 | 0.47 | 0.42 |
| Net Debt / EBITDA | 1.46 | 1.46 | — | — | — | — | 2.69 | -1.49 | 5.28 | — | — |
| Debt / FCF | — | — | — | — | — | -0.84 | — | -1.48 | 4.32 | 16.73 | — |
| Interest Coverage | 0.56 | 0.56 | -3.52 | -5.95 | -3.62 | -5.13 | -0.31 | 1.65 | -0.78 | -6.99 | -2.05 |
Short-term solvency ratios and asset-utilisation metrics
Valneva SE's current ratio of 2.61x is well above the 1.0 safety threshold, indicating strong short-term liquidity with ample room to cover current liabilities. The quick ratio of 2.14x is notably lower than the current ratio, indicating a significant portion of current assets is tied up in inventory. The current ratio has improved from 1.53x to 2.61x over the past 3 years.
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 2.61 | 2.61 | 1.65 | 1.53 | 1.59 | 1.75 | 3.13 | 2.93 | 2.22 | 2.35 | 2.51 |
| Quick Ratio | 2.14 | 2.14 | 1.37 | 1.40 | 1.25 | 1.60 | 2.50 | 2.40 | 1.69 | 1.76 | 1.93 |
| Cash Ratio | 1.47 | 1.47 | 0.79 | 1.04 | 0.94 | 1.16 | 1.56 | 1.79 | 0.89 | 0.91 | 0.90 |
| Asset Turnover | — | 0.34 | 0.33 | 0.58 | 0.43 | 0.25 | 0.48 | 0.49 | 0.56 | 0.45 | 0.28 |
| Inventory Turnover | 1.84 | 1.84 | 2.27 | 9.24 | 1.51 | 2.02 | 1.94 | 1.91 | 2.31 | 1.90 | 1.76 |
| Days Sales Outstanding | — | 75.78 | 98.89 | 24.16 | 46.15 | 63.63 | 69.50 | 36.36 | 61.09 | 65.63 | 73.38 |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Valneva SE does not currently pay a dividend and has no material buyback yield, reinvesting earnings back into the business.
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — | — | — | — | — |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — | — | — | — | — |
| Shares Outstanding | — | $70M | $69M | $58M | $49M | $45M | $46M | $41M | $39M | $37M | $36M |
Compare VALN with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
| VALNYou | $963M | -55.3 | 26.3 | — | 41.9% | 7.9% | -7.9% | 4.5% | 6.6 |
| BNTX | $28B | -33.7 | — | — | 80.3% | -47.8% | -3.4% | -10.5% | — |
| MRNA | $21B | -5.8 | — | — | 54.2% | -123.3% | -28.8% | -27.0% | — |
| SMMT | $13B | -11.5 | — | — | — | — | -206.1% | -163.4% | — |
| PCVX | $8B | -11.0 | — | — | — | — | -25.6% | -24.7% | — |
| CDTX | $7B | -8.3 | — | — | 100.0% | -13811.9% | -219.0% | — | — |
| SCNI | $3B | 0.1 | — | — | -88.1% | -1312.8% | 177.4% | -61.1% | — |
| NVAX | $2B | 3.9 | 3.7 | — | 93.5% | 40.3% | — | — | 0.5 |
| VIR | $1B | -2.9 | — | — | 82.9% | -682.7% | -45.7% | -40.3% | — |
| CVAC | $1B | 6.5 | 3.1 | 12.6 | 80.2% | 33.2% | 26.7% | 65.0% | 0.2 |
| CRMD | $559M | -23.8 | — | — | 92.7% | -51.4% | -23.2% | -46.8% | — |
| Healthcare Median | — | 23.7 | 13.8 | 18.8 | 65.8% | -6.3% | -37.3% | -15.0% | 3.1 |
Peers based on L4 peer group classification. Compare multiple stocks →
Includes 30+ ratios · 20 years · Updated daily
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorSee our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationSee how VALN stacks up against sector leader BioNTech SE.
Start ComparisonValneva SE's current P/E ratio is -55.3x. This places it at the 50th percentile of its historical range.
Valneva SE's current EV/EBITDA is 26.3x. This enterprise value multiple compares the company's total value (equity + debt - cash) to its EBITDA. The historical average is 10.8x.
Valneva SE's return on equity (ROE) is -7.9%. The historical average is -26.8%.
Based on historical data, Valneva SE is trading at a P/E of -55.3x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
Valneva SE has 41.9% gross margin and 7.9% operating margin.
Valneva SE's Debt/EBITDA ratio is 6.6x, indicating high leverage. A ratio above 4x may signal elevated financial risk.